13G Filing: Great Point Partners and Foamix Pharmaceuticals Ltd (FOMX)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Schedule 13G/A

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 2)*

 

Foamix Pharmaceuticals Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

M46135105

(CUSIP Number)

April 10, 2017

(Date of Event which Requires Filing of this
Statement)

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:

x	Rule 13d-1(b)
o	Rule 13d-1(c)
o	Rule 13d-1(d)

*The remainder of this cover
page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Persons who respond to the collection of information
contained in this form are not required to respond unless the form displays a currently valid OMB control number.